Statins work by poisoning an enzyme (HMG-CoA reductase) which is needed to produce cholesterol, adrenal and sex hormones, memory proteins and maintain cell energy. The highest concentration of cholesterol in the body is found in the brain. There were 36,605 reports of brain dysfunction from the FDA Adverse Events Databases which included memory impairment, transient cases of global amnesia, confusion, paranoia, disorientation, depression, and dementia related to statin use. Remember, this number is thought to represent only 1-10% of the true number of adverse drug reactions.
Why should a 2% cardiovascular risk reduction in a drug that has shown nothing before this be considered a success? And, keep in mind, that this risk reduction did not include the most meaningful risk reduction–death. This study found no difference in the most important endpoints: overall deaths, cardiovascular deaths, or coronary deaths. Why does my profession accept this mediocrity? Not only do they accept it, they embrace it. It is pathetic. Folks, we spend too much money on drugs that provide little, if any, benefit. In fact, we spend more on drugs than any country on the face of the earth and we lag behind every major Western country on every important health and disease indicator. This study should be the last nail in the coffin for Vytorin. It is a failed drug that has little usefulness. We would be better served to remove it from the marketplace.
Here is a fact that has been known for quite a long time, but it is still news to many people: People with higher cholesterol levels live longer than people with lower cholesterol levels. The reason why this fact is not well-known in the general public is because it would put a huge dent into a $100 BILLION drug market for statin drugs - drugs that lower your cholesterol. With approximately one out of every 4 Americans over the age of 50 currently prescribed a statin drug, a drug with very serious side effects, this is certainly one issue you should investigate yourself.
Lawsuits filed against Pfizer for their blockbuster cholesterol-lowering drug Lipitor reached 1162 cases filed in August. Almost all of theses cases have been filed since April, when a new study was released linking Type 2 diabetes in women with the popular statin drug. Attorneys filing claims for the victims have stated the cases could well reach 10,000. Cholesterol-lowering statin drugs are a $100 billion a year industry. Lipitor is by far the most profitable drug in the history of mankind among all pharmaceutical products, let alone being the most profitable cholesterol drug before its patent expired at the end of 2011. Sales to date from this one particular cholesterol-lowering statin drug have exceeded $140 billion. Lipitor benefited from the change in marketing laws in 1997 that allowed pharmaceutical companies in the U.S. to advertise their products directly to consumers. Pfizer convinced an entire generation of Americans that they needed a pill to lower their cholesterol in order to prevent heart disease, in what will go down as one of the most brilliant and unethical marketing schemes of all time. After Lipitor’s patent expired at the end of 2011, the FDA issued its first warnings against statin drugs, which includes: liver injury, memory loss, diabetes, and muscle damage. Soon after issuing these warnings, the lawsuits started trickling in. Today, with more and more studies being published linking statin drug use to various side effects, those lawsuits have become a tidal wave, even though you are not likely to hear much about this in the mainstream media.
A study just published in the international journal Drug Safety found a positive association between regular statin drug use and Bell's palsy, a neurologic disorder. This study confirms what Dr. Stephanie Seneff published back in 2009, showing how stain drugs used to lower cholesterol could be a main cause of Alzheimer's and other neurological diseases in old age.
We reported last week here at Health Impact News that lawsuits filed against a manufacturer of cholesterol-lowering statin drugs had exceeded 1,000 claims just since April this year, primarily against Pfizer's Lipitor. Today, the mainstream media has finally picked up the story, as Reuter's ran a report widely distributed over several mainstream news sites. In the Reuters' story, Jessica Dye reports that U.S. women who say Lipitor gave them type-2 diabetes shot up from 56 to almost 1,000 court lawsuits in less than 5 months. Dye also interviewed H. Blair Hahn of Mount Pleasant, South Carolina, the lead lawyer appointed to represent Lipitor plaintiffs in federal court. "We will ask a jury to decide what it's worth to take five years of someone's life," Hahn reportedly said. Hahn also stated that the 1,000 cases filed so far represent 4,000 women, and that the number of cases could ultimately reach 10,000 or more.
Fresh off recent news that more than 1,000 people have filed lawsuits for damages due to cholesterol-lowering drugs since April this year, comes the remarkable story reported in the Wall Street Journal that Regeneron Pharmaceuticals, Inc. and Sanofi SA are spending $67.5 million to purchase a voucher that will allow them to get the FDA to fast-track approval of a new class of cholesterol drugs. By purchasing this voucher, they hope to beat rival drug company Amgen, Inc. in being first to market with these new cholesterol-lowering drugs. Bloomberg Businessweek is reporting that this is a first-of-its-kind deal offered by the FDA to fast track a drug through the purchase of a voucher. However, the original voucher issued by the FDA was not even for a cholesterol lowering drug. It was originally issued to BioMarin Pharmaceutical under a 2012 law designed to reward companies for investing in drugs for rare childhood diseases. This law, which the FDA says was "intended to encourage the development of treatments for rare pediatric diseases," also allowed those awarded such vouchers to sell them to other drug companies for the development of other drugs. This has effectively created a type of legal "black market" where drug companies can sell these vouchers to the highest bidder, even though they were intended by the FDA to approve new drugs specifically for the "development of treatments for rare pediatric diseases." Since this apparently does not raise any ethical questions in the mainstream media, I will raise them here.
Top Irish surgeon warns statins raise chances of cancer and Parkinson's in otherwise healthy people. Sherif Sultan, of University College Hospital in Galway, warned that statin use can increase the risk of diabetes, cataracts and male impotence. "They can also significantly increase the risk of cancer and neurodegenerative disorders such as Parkinson's disease in the elderly, along with a myriad of infectious diseases," he said.
The $100 billion dollar cholesterol-lowering statin drug industry is under attack, as thousands of Americans are filing lawsuits against the manufacturers cholesterol-lowering drugs such as Lipitor. Research continues to confirm just how dangerous these drugs are, with yet another study published recently linking increased statin drug use to type 2 diabetes. One in four Americans over the age of 45 are currently on statin drugs. In spite of the increased research linking these drugs to diabetes, Alzheimer's Disease, liver damage, breast cancer, among many others, government-funded Big Pharma agencies continue to promote statin drugs and are attempting to get more Americans to take them. New guidelines put out by the American Heart Association earlier this year (2014) would more than double the number of Americans taking statin drugs. If we follow the pattern of Big Pharma when their products can no longer be supported in a free market due to lack of consumer confidence and demand, and massive litigation due to faulty products, they will probably seek some kind of government protection from these lawsuits. Such government protection will allow them to distribute their cholesterol drugs through government drug programs such as Medicare and Medicaid, and the new Obamacare. With the baby boomer generation heading into their senior years, it is just too large of a market for them to give up without a fight. The logic they will use with politicians in Washington D.C. will be very similar to the logic currently used by the vaccine market: Americans are too stupid to know better, so we need laws to protect us and our products against litigation so we can continue to manufacture and distribute them to people who don't want them, because they don't realize how much they need our drugs. We are currently living in the Dark Ages when it comes to health freedom, as today's pharmaceutical companies are the biggest criminals in the marketplace, having reached settlements in criminal medical abuses that reach into the billions of dollars. Yet the government continues to not only recommend their products, but purchase and distribute them with YOUR tax dollars via government funded programs such as Medicare, Medicaid, and Obamacare. As a consumer, you must resist purchasing these toxic products, and fight against any kind of mandated "health program" that forces you to purchase or take their products. History will look back on these Dark Days of medical tyranny with horror. In the meantime, don't become a fatality and statistic to the cholesterol drug scam! If you are responsible for caring for any seniors, help them to not become a fatality or statistic as well, by being informed and taking a stand for your rights!
Before its patent expired, Lipitor was the best-selling drug of all time. Lipitor, the drug that artificially lowers cholesterol, outsold almost all other drugs combined during the height of its run, before the patent ran out allowing generics to enter the market. The FDA did not issue warnings about the dangerous side effects of cholesterol-lowering drugs until after Lipitor's patent expired. The information here comes from an attorney, as attorneys across the nation see the economic opportunities now to sue Pfizer for damage done to millions of peoples' health.